Adagio Medical is a medical device company developing catheter-based ablation systems for treating cardiac arrhythmias, primarily ventricular tachycardia, using proprietary Ultra-Low Temperature Ablation technology. The company's lead product, the vCLAS Cryoablation System, is designed to treat ventricular tachycardia patients with a double freeze-thaw-freeze protocol that offers advantages over conventional radiofrequency ablation approaches, including greater lesion depth, larger lesion size, and elimination of fluid irrigation requirements. Adagio competes in the electrophysiology device market, which serves hospitals and cardiac centers performing ablation procedures, and generates revenue through product sales to healthcare providers treating structural heart disease patients.